生物技术公司Kymera Therapeutics(KYMR)今日盘中股价大幅下跌7.27%,引发市场广泛关注。据统计,截至收盘KYMR报33.34美元,成交量3.18万股,振幅4.84%。
公司最新公布的2024年第四季度财报显示,KYMR当季每股亏损0.88美元,远高于华尔街分析师预期的0.78美元亏损。公司当季营收也仅达739万美元,不及分析师预期的1182万美元。与去年同期相比,营收更是大幅下滑84.56%。
显而易见,Kymera Therapeutics业绩大幅逊于市场预期,给投资者带来了较大的不确定性和失望。公司财务数据的疲软表现,可能是导致KYMR股价今日大跌的主要诱因之一。对于生物科技公司而言,有突破性的研发进展和业务增长前景,往往是维系估值水平和吸引市场资金的关键所在。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.